Your new post is loading...
arGEN-X - The SIMPLE Antibody™ platform is uniquely suited to therapeutic human antibody discovery.
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
POTELLIGENT® enables monoclonal antibodies to be manufactured and produced in 100% fucose-free form, resulting in significant enhancement of antibody-dependent cellular cytotoxicity (ADCC) and tumor cell-killing activity. POTELLIGENT® is exclusively licensed by BioWa, Inc., a member of the Kyowa Hakko Kirin Group.
We are applying POTELLIGENT® to our own and our partners’ antibody products under a non-exclusive license from BioWa.
POTELLIGENT® has been commercially validated by mogamulizumab (Poteligeo®), a defucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), developed by Kyowa Hakko Kirin and approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.